The ARCHITECT galectin-3 assay: Comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure

Wouter C. Meijers, A. Rogier Van Der Velde, Rudolf A. De Boer*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

30 Citations (Scopus)

Abstract

Heart failure (HF) is a common disease and affects millions of patients worldwide. Diagnosis, risk assessment and treatment of HF are difficult and therefore there is a need for additional tools to improve clinical performance. Biomarkers may be helpful in this respect. Galectin-3 is a relatively new biomarker that has been shown to have strong associations with the development of HF. Galectin-3 plays a role in inflammation and fibrosis, which are key elements in the pathophysiology of HF. Circulating plasma or serum galectin-3 levels have strong associations with the severity of HF and may be used to prognosticate or risk-stratify HF patients. Currently, there are several commercially available assays that can measure circulating galectin-3. This article describes the role galectin-3 plays in HF and its prognostic consequences. We will summarize the technical specifications of various manual and automated galectin-3 assays, which may help in HF management.

Original languageEnglish
Pages (from-to)257-266
Number of pages10
JournalExpert Review of Molecular Diagnostics
Volume14
Issue number3
DOIs
Publication statusPublished - Apr 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'The ARCHITECT galectin-3 assay: Comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure'. Together they form a unique fingerprint.

Cite this